Summary of SenesTech Investor Conference Company Overview - **Company Name**: SenesTech - **Ticker Symbol**: SNES - **Industry**: Rodent Control Solutions - **Key Product**: Evolve (rodent birth control product) Core Industry Insights - Rodents are a significant public health issue, causing over **$27 billion** in infrastructure damage annually in the U.S. alone and destroying nearly **20%** of the world's food supply [2][3] - The global market for rodenticides is approximately **$4.5 billion**, with the U.S. market spending over **$1 billion** annually [11][23] - Traditional rodenticides are facing increasing resistance and regulatory restrictions, leading to a demand for humane and sustainable alternatives [10][24] Key Product Features and Innovations - SenesTech's products are the only registered rodent birth control solutions available commercially, focusing on suppressing rodent reproduction rather than just extermination [2][5] - The product **Evolve** has become the top-selling item, significantly changing the company's trajectory and expanding market reach [7][8] - Evolve has shown to reduce rat populations by **90%** when integrated into pest management programs [6][8] Financial Performance - **2024 Revenue Growth**: Up **56%**, driven by a **107%** increase in e-commerce sales due to Evolve [8][25] - **Gross Margin**: Improved to **65%** in Q2 2025, up from **54%** in the previous year [18][25] - **Revenue Breakdown**: E-commerce accounted for **56%** of Q2 sales, with a **78%** increase year-over-year [16][17] Market Strategy and Expansion - SenesTech is targeting multiple verticals: consumer, cities and governments, pest management, agribusiness, facilities management, and industrial applications [11][24] - The company has established a multi-channel distribution strategy, with **60%** of revenue coming from e-commerce platforms like Amazon and Walmart [11][12] - Recent municipal deployments in cities like Chicago and New York City are expected to drive future growth [14][15] Regulatory and Competitive Advantages - SenesTech has a regulatory head start with **EPA** approvals and a **FIFRA 25(b)** exemption, which competitors will find challenging to replicate [9][10] - The company holds proprietary know-how and has conducted extensive efficacy studies, establishing a strong competitive position in the market [9][10] Future Outlook - The company aims to achieve profitability with a break-even point estimated at **$6.5 to $7 million** in annual revenues [20][25] - Continued focus on operational efficiencies and growth in e-commerce, municipal, and international markets is expected to drive revenue [23][24] Additional Insights - The introduction of Evolve has allowed SenesTech to expand its market to include mice, enhancing growth opportunities [23] - The company has reduced cash burn by **$2 million** annually and is prioritizing investments in e-commerce and government sales [24][25]

Core Points - SenesTech, Inc. will participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025, with a webcast presentation and one-on-one meetings with investors [1][3] - The webcast presentation is scheduled for 2:45 p.m. ET and will be accessible online, with a replay available after the event [2] - SenesTech focuses on humane management of animal pest populations through fertility control, with products like Evolve rodent birth control enhancing pest management effectiveness [3] Company Overview - SenesTech is dedicated to creating healthier environments by managing animal pest populations humanely through fertility control [3] - The company's mission includes creating cleaner cities, more efficient businesses, and healthier communities with humane, effective, and sustainable products [3] Contact Information - For investor inquiries, Robert Blum from Lytham Partners can be contacted at 602-889-9700 [6] - Tom Chesterman, Chief Financial Officer of SenesTech, can be reached at 928-779-4143 for company-related inquiries [6]

Core Insights - SenesTech, Inc. has launched its Evolve™ Rat Birth Control product on HomeDepot.com, enhancing consumer accessibility and retail distribution [1][5][6] - Evolve™ Rat is the first non-toxic solution targeting rat reproduction, providing a humane and sustainable method for managing rat populations [2][10] - The partnership with Home Depot is expected to significantly boost the brand's visibility and revenue potential, given Home Depot's extensive online transaction volume [5][6] Company Overview - SenesTech focuses on humane pest management through fertility control, aiming to create healthier environments by reducing reliance on traditional poisons [7] - The company's mission includes enhancing pest management programs and promoting sustainable practices [7] Product Details - Evolve™ Rat is a soft bait made from food-grade ingredients, designed to reduce rat populations by targeting reproduction rather than relying on lethal methods [10] - The product is easy to use and integrates seamlessly into existing pest control programs, making it suitable for various settings [10] Market Opportunity - Home Depot processed over 395 million online transactions in 2024, indicating a substantial market opportunity for Evolve™ Rat [5] - The launch on HomeDepot.com positions SenesTech for accelerated adoption and stronger revenue streams by reaching millions of potential customers [5][6]

Summary of SenesTech (SNES) Conference Call - August 19, 2025 Company Overview - **Company**: SenesTech - **Ticker Symbol**: SNES - **Industry**: Biotech and Life Sciences, specifically pest control - **Core Product**: Rodent birth control solutions disrupting the rodenticide market, focusing on sustainable pest management [3][4] Key Points and Arguments Industry Context - **Rodent Problem**: Rodents cause over $27 billion in infrastructure damage annually in the U.S. and destroy nearly 20% of the world's food supply [4][5] - **Current Solutions**: Existing rodenticides are largely poisons that are ineffective and harmful, leading to resistance and bans in various jurisdictions [6][7] Product Differentiation - **Unique Approach**: SenesTech focuses on suppressing rodent reproduction rather than increasing mortality rates, with products that are humane and do not harm non-target species [11][12] - **Evolve Product**: Launched as a solid bait, it has an 18-month shelf life and is designed for both professional and DIY use, significantly expanding market reach [16][17] Market Position and Competitive Advantage - **Regulatory Head Start**: SenesTech has a FIFRA 25B minimum risk exemption and approvals in 48 states, giving it a significant advantage over competitors [18][19] - **Intellectual Property**: The company holds patents and trade secrets that protect its unique formulations and efficacy studies [20][21] Market Opportunities - **Market Size**: The U.S. rodenticide market is approximately $1 billion, with a global market of $4.5 billion [26][63] - **Target Verticals**: Key markets include consumers, cities and governments, pest management, agribusiness, facilities management, and food production [26][27] Sales and Distribution Strategy - **E-commerce Growth**: E-commerce accounts for over 60% of revenue, with a 78% increase year-over-year, driven by the popularity of Evolve [31][32] - **Municipal Deployments**: Significant traction in cities like Chicago and New York, with successful pilot programs leading to reorders and increased consumer adoption [36][38] Financial Performance - **Revenue Growth**: Total revenue is approximately $2 million annually, with Evolve sales increasing by 94%, making up 83% of second-quarter sales [51][52] - **Gross Margins**: Improved to 65.4% in Q2, driven by the profitability of the Evolve product [55] - **Cash Position**: The company ended the quarter with $6.1 million in cash, with a pro forma cash position of about $12 million, providing a runway into 2027 [60][61] Future Outlook - **Regulatory Tailwinds**: Increasing bans on traditional rodenticides and a push for humane alternatives create a favorable environment for SenesTech's products [63][64] - **Growth Strategy**: Focus on e-commerce, international markets, and government sales, with expectations for strong revenue growth and margin expansion [66][67] Additional Important Points - **International Expansion**: Successful pilot programs in markets like Hong Kong and the Netherlands, with potential for significant orders [43][44] - **Brick and Mortar Retail**: Recent agreements with distributors to expand into physical retail, with a nearly 500% increase in brick-and-mortar sales sequentially [46][47] This summary encapsulates the key insights from the SenesTech conference call, highlighting the company's innovative approach to pest control, market opportunities, and financial performance.

Company Overview - SenesTech, Inc. is a leader in fertility control for managing animal pest populations, focusing on sustainable alternatives to traditional pest control methods [3] - The company has developed ContraPest®, the first and only U.S. EPA-registered contraceptive for male and female rats, along with Evolve Rat and Evolve Mouse Birth Control, which are FIFRA 25(b) minimum-risk solutions [3] Upcoming Events - SenesTech will participate in a webcast presentation at the Lytham Partners 2025 Consumer & Technology Investor Summit on August 19, 2025, at 3:30 p.m. ET [1][2] - The webcast can be accessed through the conference home page or directly via provided links, with a replay available afterward [2] Mission and Vision - The company's mission emphasizes healthier cities, safer environments, and smarter pest management, advocating for reproductive control as the future of pest management [4]

Financial Data and Key Metrics Changes - Total revenue for Q2 2025 was $625,000, representing a 36% increase year-over-year and a 29% sequential increase [19] - EVOLVE sales increased by 94% year-over-year and accounted for 83% of total revenue, while ContraPest sales decreased by approximately 45% [19] - Gross profit margins improved to 65.4%, up from 54.2% in the same quarter last year and 64.5% sequentially [22] Business Line Data and Key Metrics Changes - EVOLVE now constitutes 83% of total quarterly revenue, with gross profit dollars up 64% compared to last year's Q2 [6][22] - E-commerce sales grew by 78% year-over-year and accounted for over 50% of quarterly sales, with Amazon leading the channel [8][20] - Municipal sales saw a 538% increase year-over-year, driven by deployments in cities like Chicago and New York [21] Market Data and Key Metrics Changes - E-commerce sales were up 78% compared to last year and up 18% sequentially, with significant growth in brick-and-mortar retail sales, which increased nearly 500% sequentially [8][21] - International sales included a follow-on order from the Caribbean, with ongoing regulatory approvals in Australia and New Zealand [12][21] Company Strategy and Development Direction - The company is focused on expanding its market presence through the EVOLVE product line, which has opened new verticals and distribution channels [5][16] - Plans are in place to accelerate e-commerce growth and expand into agricultural applications, where significant opportunities exist [32][14] - The company aims to achieve cash flow breakeven at approximately $1,500,000 in quarterly revenue, with expectations for growth in 2026 [25][39] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in continued growth from city and government trials, anticipating increased orders as results from trials prove successful [33] - The company is optimistic about its position in the market, citing a large addressable global market and regulatory tailwinds [28] - Management highlighted the importance of focusing on the EVOLVE product line to maximize market penetration and operational efficiency [49] Other Important Information - The company ended the quarter with $6,100,000 in cash, following successful financing activities [26] - The new manufacturing facility has the capacity to produce approximately $10,000,000 in revenue, with plans for further expansion [34] Q&A Session Summary Question: Should we expect incremental improvements to gross margins in the coming quarters? - Yes, management expects margins to remain consistent and possibly improve [30] Question: Is there room to accelerate e-commerce growth with additional digital marketing spend? - Yes, plans are in place to accelerate growth across all channels [31] Question: Should we expect higher volumes from cities where the product has been launched? - Yes, as trials prove successful, increased orders and revenues are anticipated [33] Question: What is the potential capacity in terms of dollars of the expanded manufacturing facility? - The facility can produce roughly $10,000,000 in revenue with current operations [34] Question: Are you planning to do more capital raises in the future? - No further financings are anticipated in the near future, as the company has sufficient cash to reach cash flow profitability [36] Question: Would a full-scale New York City expansion require a big capital investment? - No significant capital investment is required immediately, but future expansions may need some capital [38] Question: Do you need to hire additional people to meet growth expectations? - Yes, the company is hiring salespeople and expanding its field team to support growth [40] Question: Are there any active trials that have not been announced? - Yes, there are ongoing trials that have not yet been disclosed [42] Question: How long before you are in store with Tractor Supply? - The company hopes to have news on this in the coming months [46] Question: Can you specify how OpEx will be cut? - Cuts have already been made, and there are no specific plans for further reductions at this time [47]

[PART I — FINANCIAL INFORMATION](index=4&type=section&id=PART%20I%20%E2%80%94%20FINANCIAL%20INFORMATION) [Item 1. Financial Statements](index=4&type=section&id=Item%201.%20Financial%20Statements) Presents SenesTech, Inc.'s unaudited condensed financial statements, covering balance sheets, operations, and cash flows [Condensed Balance Sheets](index=4&type=section&id=Condensed%20Balance%20Sheets) Details the company's financial position at specific dates, outlining assets, liabilities, and stockholders' equity | Metric | June 30, 2025 (unaudited) (in thousands) | December 31, 2024 (in thousands) | | :-------------------------------- | :--------------------------------------- | :------------------------------- | | Cash and cash equivalents | $6,055 | $1,307 | | Total current assets | $7,474 | $2,813 | | Total assets | $10,365 | $3,278 | | Total current liabilities | $810 | $561 | | Total liabilities | $3,388 | $767 | | Total stockholders' equity | $6,977 | $2,511 | - Total assets increased significantly from **$3,278 thousand** at December 31, 2024, to **$10,365 thousand** at June 30, 2025, primarily due to a substantial increase in cash and cash equivalents[11](index=11&type=chunk) - Total stockholders' equity increased from **$2,511 thousand** at December 31, 2024, to **$6,977 thousand** at June 30, 2025, reflecting new equity issuances[11](index=11&type=chunk) [Condensed Statements of Operations and Comprehensive Loss](index=5&type=section&id=Condensed%20Statements%20of%20Operations%20and%20Comprehensive%20Loss) Presents the company's financial performance over periods, detailing revenues, expenses, gross profit, and net loss | Metric | Three Months Ended June 30, 2025 (in thousands) | Three Months Ended June 30, 2024 (in thousands) | Six Months Ended June 30, 2025 (in thousands) | Six Months Ended June 30, 2024 (in thousands) | | :------------------------------------ | :---------------------------------------------- | :---------------------------------------------- | :-------------------------------------------- | :-------------------------------------------- | | Revenues, net | $625 | $459 | $1,110 | $874 | | Cost of sales | $216 | $210 | $388 | $490 | | Gross profit | $409 | $249 | $722 | $384 | | Research and development | $427 | $467 | $845 | $837 | | Selling, general and administrative | $1,596 | $1,384 | $3,154 | $2,992 | | Total operating expenses | $2,023 | $1,851 | $3,999 | $3,829 | | Loss from operations | $(1,614) | $(1,602) | $(3,277) | $(3,445) | | Net loss and comprehensive loss | $(1,616) | $(1,584) | $(3,281) | $(3,416) | | Net loss per share - basic and diluted | $(0.87) | $(3.08) | $(2.08) | $(6.64) | - Net revenues increased by **36%** for the three months ended June 30, 2025, and by **27%** for the six months ended June 30, 2025, driven by Evolve product sales[13](index=13&type=chunk) - Gross profit increased by **64%** for the three months ended June 30, 2025, and by **88%** for the six months ended June 30, 2025, reflecting improved margins[13](index=13&type=chunk) [Condensed Statements of Cash Flows](index=6&type=section&id=Condensed%20Statements%20of%20Cash%20Flows) Summarizes cash inflows and outflows from operating, investing, and financing activities over specific periods | Metric | Six Months Ended June 30, 2025 (in thousands) | Six Months Ended June 30, 2024 (in thousands) | | :------------------------------------ | :-------------------------------------------- | :-------------------------------------------- | | Net cash used in operating activities | $(2,707) | $(3,416) | | Net cash used in investing activities | $(83) | $(41) | | Net cash provided by financing activities | $7,538 | $14 | | Increase (decrease) in cash and cash equivalents | $4,748 | $(3,443) | | Cash and cash equivalents, end of period | $6,055 | $1,952 | - Net cash provided by financing activities significantly increased to **$7,538 thousand** for the six months ended June 30, 2025, from **$14 thousand** in the prior year, primarily due to proceeds from warrant exercises and common stock issuances[16](index=16&type=chunk) - Cash and cash equivalents at the end of the period increased to **$6,055 thousand** as of June 30, 2025, from **$1,952 thousand** in the prior year, driven by financing activities[16](index=16&type=chunk) [Notes to Condensed Financial Statements](index=7&type=section&id=Notes%20to%20Condensed%20Financial%20Statements) Provides detailed explanations and disclosures supporting the condensed financial statements [NOTE 1: BASIS OF PRESENTATION](index=7&type=section&id=NOTE%201:%20BASIS%20OF%20PRESENTATION) Describes the company's business, product lines, and financial statement basis, including going concern considerations - SenesTech, Inc. develops and commercializes fertility control products for animal pest populations, focusing on rats and mice with products like ContraPest, Evolve Rat, and Evolve Mouse[18](index=18&type=chunk) - Evolve Rat, launched in January 2024, is the current lead product, a soft bait exempt from federal registration and authorized for sale in **48 states and territories**[19](index=19&type=chunk)[20](index=20&type=chunk) - Evolve Mouse, launched in May 2024, is a variation of the soft bait formulation, also a minimum risk pesticide, authorized for sale in **37 states and territories**[21](index=21&type=chunk) - The company has incurred significant operating losses since inception, with an accumulated deficit of **$139.4 million** as of June 30, 2025, raising substantial doubt about its ability to continue as a going concern[23](index=23&type=chunk)[25](index=25&type=chunk) - Management expects current cash and anticipated revenue, combined with additional equity sales, to fund operations through at least the end of fiscal 2027[27](index=27&type=chunk) [NOTE 2: BALANCE SHEET COMPONENTS](index=10&type=section&id=NOTE%202:%20BALANCE%20SHEET%20COMPONENTS) Provides detailed breakdowns of key balance sheet accounts like cash, receivables, inventory, and liabilities Cash and Cash Equivalents (in thousands) | Date | Amount | | :--- | :----- | | June 30, 2025 | $6,055 | | December 31, 2024 | $1,307 | Accounts Receivable, Net (in thousands) | Date | Amount | | :--- | :----- | | June 30, 2025 | $470 | | December 31, 2024 | $335 | Allowance for Uncollectible Accounts (in thousands) | Period | 2025 | 2024 | | :--- | :--- | :--- | | Balance as of beginning of period | $4 | $4 | | Increase in provision (Six Months Ended June 30) | $6 | $2 | | Balance as of end of period (June 30) | $10 | $4 | Inventory, Net (in thousands) | Date | Amount | | :--- | :----- | | June 30, 2025 | $711 | | December 31, 2024 | $794 | Accrued Expenses (in thousands) | Date | Amount | | :--- | :----- | | June 30, 2025 | $564 | | December 31, 2024 | $278 | Notes Payable (in thousands) | Year | Principal Payments | | :--- | :----------------- | | 2025 | $28 | | 2026 | $61 | | 2027 | $68 | | 2028 | $65 | | 2029 | $12 | | Total principal payments | $234 | | Less: current portion | $(59) | | Notes payable, less current portion | $175 | [NOTE 3: FAIR VALUE MEASUREMENTS](index=12&type=section&id=NOTE%203:%20FAIR%20VALUE%20MEASUREMENTS) Explains the fair value measurement of financial instruments, noting approximations due to short maturities - The carrying amounts of financial instruments like accounts payable and accrued liabilities approximate fair value due to their short maturities[40](index=40&type=chunk) [NOTE 4: LEASES](index=14&type=section&id=NOTE%204:%20LEASES) Details the company's operating lease arrangements, including costs and future liability maturities - In August 2024, the company entered into a new operating lease for its corporate headquarters and manufacturing/research operations, commencing April 2025 and expiring in 2035[42](index=42&type=chunk) Operating Lease Cost (in thousands) | Period | 2025 | 2024 | | :--- | :--- | :--- | | Three Months Ended June 30 | $101 | $57 | | Six Months Ended June 30 | $173 | $113 | Operating Lease Liability Maturities as of June 30, 2025 (in thousands) | Year | Amount | | :--- | :----- | | 2025 | $83 | | 2026 | $331 | | 2027 | $338 | | 2028 | $348 | | 2029 | $358 | | Thereafter | $2,245 | | Total operating lease payments | $3,703 | | Less: imputed interest | $(1,248) | | Total operating lease liability | $2,455 | [NOTE 5: STOCK-BASED COMPENSATION](index=14&type=section&id=NOTE%205:%20STOCK-BASED%20COMPENSATION) Outlines the company's stock-based compensation plans, option activity, and related expenses - The 2018 Equity Incentive Plan was amended on July 11, 2024, increasing authorized shares to **207,071**, with **32,182 shares** available for issuance as of June 30, 2025[43](index=43&type=chunk) Stock Option Activity (Six Months Ended June 30, 2025) | Metric | Number of Options | Weighted Average Exercise Price Per Share | | :-------------------------------- | :---------------- | :---------------------------------------- | | Outstanding as of Dec 31, 2024 | 147,616 | $27.13 | | Granted | 28,057 | $3.09 | | Forfeited | (11) | $2,497.70 | | Outstanding as of June 30, 2025 | 175,662 | $23.14 | | Exercisable as of June 30, 2025 | 81,175 | $46.15 | Stock-Based Compensation Expense (in thousands) | Expense Category | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :-------------------------------- | :------------------------------- | :------------------------------- | :----------------------------- | :----------------------------- | | Research and development | $3 | $4 | $6 | $8 | | Selling, general and administrative | $87 | $84 | $175 | $165 | | Total | $90 | $88 | $181 | $173 | - As of June 30, 2025, unrecognized stock-based compensation related to unvested options totaled **$245,000**, to be recognized over a weighted average period of **2.1 years**[48](index=48&type=chunk) [NOTE 6: STOCKHOLDERS' EQUITY](index=17&type=section&id=NOTE%206:%20STOCKHOLDERS'%20EQUITY) Details changes in stockholders' equity, including stock issuances, warrant exercises, and net loss Stockholders' Equity Activity (Six Months Ended June 30, 2025, dollars in thousands) | Metric | Shares | Common Stock Amount | Additional Paid-In Capital | Accumulated Deficit | Total | | :------------------------------------ | :------- | :------------------ | :------------------------- | :------------------ | :---- | | Balances as of Dec 31, 2024 | 1,035,893 | $1 | $138,607 | $(136,097) | $2,511 | | Stock-based compensation | — | — | $181 | — | $181 | | Issuance of common stock, net | 854,660 | $1 | $2,705 | — | $2,706 | | Issuance of common stock upon exercise of warrants, net | 1,873,590 | $2 | $4,858 | — | $4,860 | | Net loss | — | — | — | $(3,281) | $(3,281) | | Balances as of June 30, 2025 | 3,764,143 | $4 | $146,351 | $(139,378) | $6,977 | - In June 2025, the company completed a warrant inducement transaction, issuing **1,458,872 shares** of common stock from warrant exercises, generating gross proceeds of **$4.5 million** before costs[49](index=49&type=chunk) - In March 2025, another warrant inducement transaction resulted in the issuance of **374,718 shares** of common stock, generating gross proceeds of **$1.1 million** before costs[51](index=51&type=chunk) - During the first half of 2025, **854,660 shares** of common stock were sold under an At-The-Market (ATM) Facility for gross proceeds of **$3.0 million**[53](index=53&type=chunk) [NOTE 7: COMMON STOCK WARRANTS](index=19&type=section&id=NOTE%207:%20COMMON%20STOCK%20WARRANTS) Summarizes common stock warrant activity, including issuances, exercises, and fair value measurements Common Stock Warrant Activity (Six Months Ended June 30, 2025) | Metric | Shares | Weighted Average Exercise Price Per Share | Weighted Average Remaining Contractual Term (years) | | :-------------------------------- | :------- | :---------------------------------------- | :-------------------------------------------------- | | Outstanding as of Dec 31, 2024 | 1,307,842 | $12.63 | 3.4 | | Issued | 3,049,424 | $3.77 | 1.2 | | Exercised | (1,873,590) | $2.90 | — | | Expired | (81,073) | $21.95 | — | | Outstanding as of June 30, 2025 | 2,402,603 | $8.12 | 1.8 | - In connection with the June 2025 Warrant Inducement, new warrants to purchase **1,458,872 shares** were issued at an exercise price of **$4.15 per share**, exercisable for **1.3 years**, with an estimated fair value of **$4.1 million**[56](index=56&type=chunk) - In connection with the March 2025 Warrant Inducement, new warrants to purchase **1,498,872 shares** were issued at an exercise price of **$2.90 per share**, exercisable for **1.5 years**, with an estimated fair value of **$1.5 million**[58](index=58&type=chunk) [NOTE 8: LOSS PER SHARE](index=20&type=section&id=NOTE%208:%20LOSS%20PER%20SHARE) Explains basic and diluted loss per share, noting anti-dilutive securities due to net losses - Basic and diluted loss per share are the same for all periods presented because potentially dilutive securities were anti-dilutive due to net losses[60](index=60&type=chunk) Shares Excluded from Diluted Net Loss Per Share Calculation (in thousands) | Security Type | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :------------ | :------------------------------- | :------------------------------- | :----------------------------- | :----------------------------- | | Common stock warrants | — | — | — | — | | Stock options | — | 49 | — | 167 | [NOTE 9: SEGMENT INFORMATION](index=21&type=section&id=NOTE%209:%20SEGMENT%20INFORMATION) Identifies the company's single operating segment and details revenue and accounts receivable concentration - The company operates in a single operating segment: the formulation, development, marketing, and sale of fertility control products for pest populations[62](index=62&type=chunk) Percentage of Revenue Attributable to Major Customers | Customer | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :--------- | :------------------------------- | :------------------------------- | :----------------------------- | :----------------------------- | | Customer A | 30 % | 5 % | 30 % | 5 % | | Customer B | 5 % | 16 % | 6 % | 11 % | Percentage of Total Accounts Receivable Attributable to Major Customers | Customer | June 30, 2025 | December 31, 2024 | | :--------- | :------------ | :---------------- | | Customer A | 38 % | 30 % | | Customer B | 6 % | 20 % | | Customer C | 11 % | — % | [NOTE 10: CONTINGENCIES](index=21&type=section&id=NOTE%2010:%20CONTINGENCIES) Discloses information regarding legal proceedings, including a lawsuit filed against the company - Liphatech Inc. commenced an action against the company in December 2024, alleging breach of contract, misappropriation of trade secrets, unfair competition, and unjust enrichment[65](index=65&type=chunk) - The company believes it has strong defenses and is actively defending the case; the outcome is not known or probable, and no specific damages have been claimed or accrued[65](index=65&type=chunk) [NOTE 11: SUBSEQUENT EVENTS](index=23&type=section&id=NOTE%2011:%20SUBSEQUENT%20EVENTS) Reports significant events occurring after the balance sheet date, including recent warrant inducement transactions - On August 5, 2025, the company completed a warrant inducement transaction, issuing **1,458,872 shares** of common stock from existing warrant exercises, generating gross proceeds of **$6.3 million**[68](index=68&type=chunk) - This transaction involved issuing new warrants for **2,188,308 shares** of common stock at an exercise price of **$5.25 per share**, expiring **15 months** after the resale registration statement's effective date[68](index=68&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=24&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Provides management's perspective on the company's financial condition, operational results, liquidity, and future funding needs [Forward-Looking Statements](index=24&type=section&id=Forward-Looking%20Statements) Highlights that the report contains forward-looking statements subject to risks and uncertainties regarding future financial performance - The report contains forward-looking statements regarding future operating results, financial position, business strategy, and objectives, which are subject to known and unknown risks and uncertainties[72](index=72&type=chunk)[73](index=73&type=chunk) - Key forward-looking statements include expectations of continued significant expenses and operating losses, the need for additional financing, and the ability to achieve profitability or positive cash flows[72](index=72&type=chunk)[74](index=74&type=chunk) [Overview](index=27&type=section&id=Overview) Summarizes the company's financial performance, accumulated deficit, cash position, and factors critical to long-term success - The company incurred a net loss of **$1.6 million** for the three months ended June 30, 2025, and expects continued losses, primarily funding operations through equity sales[78](index=78&type=chunk) - As of June 30, 2025, the company had an accumulated deficit of **$139.4 million** and cash and cash equivalents of **$6.1 million**[78](index=78&type=chunk) - Long-term success depends on successful commercialization, market acceptance, effective sales, R&D success, key personnel retention, and meeting working capital needs[79](index=79&type=chunk) - Current cash and anticipated revenue, combined with additional equity sales, are expected to fund operations through at least the end of fiscal 2027, but additional financing may be needed[80](index=80&type=chunk) [Results of Operations](index=28&type=section&id=Results%20of%20Operations) Analyzes the company's financial results, including revenues, cost of sales, gross profit, and operating expenses | Metric | Three Months Ended June 30, 2025 (in thousands) | Three Months Ended June 30, 2024 (in thousands) | % Change (YoY) | Six Months Ended June 30, 2025 (in thousands) | Six Months Ended June 30, 2024 (in thousands) | % Change (YoY) | | :-------------------------------- | :---------------------------------------------- | :---------------------------------------------- | :------------- | :-------------------------------------------- | :-------------------------------------------- | :------------- | | Revenues, net | $625 | $459 | 36% | $1,110 | $874 | 27% | | Cost of sales | $216 | $210 | 3% | $388 | $490 | (21)% | | Gross profit | $409 | $249 | 64% | $722 | $384 | 88% | | Research and development | $427 | $467 | (9)% | $845 | $837 | 1% | | Selling, general and administrative | $1,596 | $1,384 | 15% | $3,154 | $2,992 | 5% | | Loss from operations | $(1,614) | $(1,602) | 1% | $(3,277) | $(3,445) | (5)% | | Net loss | $(1,616) | $(1,584) | 2% | $(3,281) | $(3,416) | (4)% | - Revenue growth was primarily driven by the Evolve product line, which represented approximately **83%** of Q2 2025 revenues (up from **58%** in Q2 2024) and **81%** of H1 2025 revenues (up from **41%** in H1 2024), offsetting a decline in ContraPest sales[83](index=83&type=chunk)[84](index=84&type=chunk)[85](index=85&type=chunk) - Gross margin improved significantly to **65.4%** in Q2 2025 (from **54.2%** in Q2 2024) and **65.0%** in H1 2025 (from **43.9%** in H1 2024), mainly due to the shift in product mix towards lower-cost Evolve products[86](index=86&type=chunk)[87](index=87&type=chunk)[89](index=89&type=chunk)[90](index=90&type=chunk) - Research and development expenses decreased by **9%** in Q2 2025 due to cost containment, despite increased facility expenses from a new manufacturing site[91](index=91&type=chunk)[92](index=92&type=chunk) - Selling, general and administrative expenses increased by **15%** in Q2 2025 and **5%** in H1 2025, primarily due to higher legal fees and franchise fees, partially offset by other cost containment efforts[93](index=93&type=chunk)[94](index=94&type=chunk) - Other income (expense), net shifted from income in 2024 to expense in 2025, driven by higher interest expense from increased notes payable and lower interest income due to reduced cash balances[95](index=95&type=chunk)[96](index=96&type=chunk) [Liquidity and Capital Resources](index=31&type=section&id=Liquidity%20and%20Capital%20Resources) Discusses the company's ability to meet its financial obligations, its funding sources, and future capital requirements - The company has an accumulated deficit of **$139.4 million** and **$6.1 million** in cash and cash equivalents as of June 30, 2025, having primarily funded operations through equity sales[98](index=98&type=chunk) - Management expects current cash, anticipated revenue, and proceeds from the August 2025 warrant exercise to fund operations through at least the end of fiscal 2027[100](index=100&type=chunk) - Additional financing may be required sooner if revenue or margin targets are not met or expenses exceed projections, with a risk of delaying or discontinuing operations if capital is unavailable[101](index=101&type=chunk) - Future expenses are expected to increase due to marketing and sales focus, strategic partnerships, regulatory approvals, manufacturing process development, R&D, intellectual property maintenance, and public company operational costs[102](index=102&type=chunk)[103](index=103&type=chunk)[104](index=104&type=chunk) Sources and Uses of Cash (Six Months Ended June 30, in thousands) | Metric | 2025 | 2024 | | :------------------------------------ | :----- | :----- | | Cash and cash equivalents, beginning of period | $1,307 | $5,395 | | Net cash used in operating activities | $(2,707) | $(3,416) | | Net cash used in investing activities | $(83) | $(41) | | Net cash provided by financing activities | $7,538 | $14 | | Increase (decrease) in cash and cash equivalents | $4,748 | $(3,443) | | Cash and cash equivalents, end of period | $6,055 | $1,952 | - Operating activities used **$2.7 million** in cash for H1 2025, primarily due to net loss, partially offset by non-cash charges and changes in operating assets/liabilities[107](index=107&type=chunk) - Financing activities provided **$7.5 million** in cash for H1 2025, mainly from warrant exercises (**$4.9 million**) and common stock issuances (**$2.7 million**)[110](index=110&type=chunk) - The August 5, 2025, warrant inducement transaction generated **$6.3 million** in gross proceeds, increasing cash and cash equivalents to approximately **$11.2 million**, which is believed to be sufficient through fiscal 2027[111](index=111&type=chunk)[112](index=112&type=chunk)[113](index=113&type=chunk) [Critical Accounting Policies and Estimates](index=36&type=section&id=Critical%20Accounting%20Policies%20and%20Estimates) States that there have been no material changes to the company's critical accounting policies and estimates - There have been no material changes to the company's critical accounting policies and estimates since the Annual Report on Form 10-K for the year ended December 31, 2024[114](index=114&type=chunk) [Item 3. Quantitative and Qualitative Disclosures About Market Risk](index=36&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) This section states that there are no applicable quantitative and qualitative disclosures about market risk for the company - The company has no applicable quantitative and qualitative disclosures about market risk[115](index=115&type=chunk) [Item 4. Controls and Procedures](index=36&type=section&id=Item%204.%20Controls%20and%20Procedures) Details the evaluation of disclosure controls and procedures and reports on any changes in internal control over financial reporting - Management, including the CEO and CFO, concluded that disclosure controls and procedures were effective as of June 30, 2025[116](index=116&type=chunk)[118](index=118&type=chunk) - There were no changes in internal control over financial reporting during the quarter that materially affected, or are reasonably likely to materially affect, internal control over financial reporting[119](index=119&type=chunk) [PART II — OTHER INFORMATION](index=37&type=section&id=PART%20II%20%E2%80%94%20OTHER%20INFORMATION) [Item 1. Legal Proceedings](index=37&type=section&id=Item%201.%20Legal%20Proceedings) This section refers to Note 10, Contingencies, for information regarding legal proceedings, indicating that the company may be involved in legal matters incidental to its normal course of business - Information regarding legal proceedings is detailed in Note 10, Contingencies, within the Notes to Condensed Financial Statements[122](index=122&type=chunk) [Item 1A. Risk Factors](index=37&type=section&id=Item%201A.%20Risk%20Factors) This section states that there have been no material changes to the risk factors previously disclosed in the company's Annual Report on Form 10-K - No material changes to risk factors have occurred since the Annual Report on Form 10-K for the year ended December 31, 2024[123](index=123&type=chunk) [Item 5. Other Information](index=37&type=section&id=Item%205.%20Other%20Information) This section reports that no directors or officers adopted or terminated Rule 10b5-1 or non-Rule 10b5-1 trading arrangements during the quarter ended June 30, 2025 - No directors or officers adopted or terminated Rule 10b5-1 or non-Rule 10b5-1 trading arrangements during the quarter ended June 30, 2025[124](index=124&type=chunk) [Item 6. Exhibits](index=37&type=section&id=Item%206.%20Exhibits) This section lists the exhibits filed as part of the Form 10-Q, including various forms of common stock purchase warrants, inducement letters, and certifications - Exhibits include forms of Series H and I Common Stock Purchase Warrants, Placement Agent Warrants, Inducement Letters, and certifications from the CEO and CFO[125](index=125&type=chunk) [SIGNATURES](index=38&type=section&id=SIGNATURES) [SIGNATURES](index=38&type=section&id=SIGNATURES) This section contains the signatures of the company's authorized officers, Joel L. Fruendt and Thomas C. Chesterman, certifying the filing of the report - The report is signed by Joel L. Fruendt, President and Chief Executive Officer, and Thomas C. Chesterman, Executive Vice President, Chief Financial Officer, Treasurer, and Secretary, on August 7, 2025[130](index=130&type=chunk)[131](index=131&type=chunk)

[Q2 2025 Financial and Operational Highlights](index=1&type=section&id=Q2%202025%20Financial%20and%20Operational%20Highlights) [Balance Sheet Highlights](index=1&type=section&id=Balance%20Sheet%20Highlights) SenesTech reported a strong cash balance of $11.2 million as of August 5, 2025, providing an operating runway through the end of 2027 - Current cash balance as of August 5, 2025, is **$11.2 million**, providing an operating runway through the **end of 2027 and beyond**[4](index=4&type=chunk) [Key Financial Metrics](index=1&type=section&id=Key%20Financial%20Metrics) The company achieved record revenue of $625,000 in Q2 2025, a 36% increase year-over-year, driven by 94% growth in Evolve products. Gross profit margin also reached a record 65.4%. Net loss remained stable at $1.6 million, with an improved Adjusted EBITDA loss of $1.4 million Q2 2025 Financial Performance Summary | Metric | Q2 2025 | Q2 2024 | Change (YoY) | | :-------------------------- | :---------- | :---------- | :----------- | | Total Revenues | $625,000 | $459,000 | +36% | | Evolve Product Sales Growth | N/A | N/A | +94% | | Gross Profit Margin | 65.4% | 54.2% | +11.2 pp | | Net Loss | $(1.6) million | $(1.6) million | 0% | | Adjusted EBITDA Loss | $(1.4) million | $(1.5) million | Improved by $0.1M | - Evolve Rodent Birth Control products sales grew **94% year-over-year**, now representing **83% of total revenue**[6](index=6&type=chunk) - Excluding **$201,000** in one-time legal expenses and **$38,000** in non-cash operating lease expense, Q2 2025 net loss would have been **$1.4 million**[6](index=6&type=chunk) [Operational and Strategic Achievements](index=1&type=section&id=Operational%20and%20Strategic%20Achievements) SenesTech saw significant traction for its Evolve Rat and Evolve Mouse products, which are now the largest revenue drivers. E-commerce revenue surged by 78% year-over-year, and municipal deployments expanded to major cities. The company also completed its move to a new manufacturing facility with automation and expanded retail partnerships - Product Expansion: The higher-margin **Evolve Rat and Evolve Mouse products**, launched in 2024, are now SenesTech's **largest revenue drivers**[7](index=7&type=chunk) - E-commerce Growth: E-commerce revenue increased **78% year-over-year**, driven by enhanced platform functionality and digital marketing[7](index=7&type=chunk) - Municipal Deployment: **Expanded municipal pilot deployments** in Q2 2025 with programs in **New York City, Chicago, Boston, Baltimore, Los Angeles County, and San Francisco**[7](index=7&type=chunk) - Retail Market Adoption: Strategic partnership with **Bradley Caldwell** led to **478% year-over-year growth** in the Retail market vertical[13](index=13&type=chunk) - Manufacturing Expansion and Automation: Completed move into a **new manufacturing facility** in **July 2025** to meet growing demand for Evolve products with **new automated capabilities**[13](index=13&type=chunk) [Management Commentary](index=2&type=section&id=Commentary) [CEO Commentary](index=2&type=section&id=CEO%20Commentary) CEO Joel Fruendt highlighted record revenue and gross margins, attributing success to rapid Evolve product adoption and disciplined OpEx management. He emphasized the strength of their multi-channel distribution strategy and the company's commitment to efficiency and profitability, aiming for breakeven goals with a strong cash position - Delivered another quarter of **record revenue and gross margins** fueled by **rapid adoption of the Evolve product line** and **disciplined OpEx management**[8](index=8&type=chunk) - Results reflect the strength of a **diverse multi-channel distribution strategy**, with momentum across E-commerce, city and government deployments, brick-and-mortar retail, and international partnerships[8](index=8&type=chunk) - Well-positioned to achieve **breakeven goals** and meet growth potential with **over $6 million in cash** at quarter-end and an **additional $6.3 million in gross proceeds** post-quarter[8](index=8&type=chunk) [Detailed Business Update](index=1&type=section&id=Detailed%20Business%20Update) [Product Development and Market Traction](index=1&type=section&id=Product%20Expansion) The Evolve Rat and Evolve Mouse products, launched in 2024, have become SenesTech's primary revenue drivers, gaining significant traction among pest management professionals and consumers due to their unique design for proactive rodent fertility control - The higher-margin **Evolve Rat and Evolve Mouse products** are uniquely designed for **proactive rodent fertility control** and continue to gain traction among pest management professionals and consumers[7](index=7&type=chunk) [Sales Channels and Market Penetration](index=1&type=section&id=Sales%20Channels%20and%20Market%20Penetration) SenesTech experienced substantial e-commerce growth, with revenue increasing 78% year-over-year across major platforms. Municipal pilot deployments expanded to several key U.S. cities, and a strategic partnership significantly boosted retail market adoption by 478% year-over-year. International expansion is also underway with pending regulatory approvals - E-commerce revenue increased **78% year-over-year** driven by enhanced platform functionality and digital marketing across Amazon, Walmart, Tractor Supply, DIYpestcontrol.com, and SenesTech.com[7](index=7&type=chunk) - **Expanded municipal pilot deployments** in Q2 2025 with programs in **New York City, Chicago, Boston, Baltimore, Los Angeles County, and San Francisco**[7](index=7&type=chunk) - Strategic partnership with **Bradley Caldwell** significantly expands and accelerates adoption of Evolve in retail locations across rural America, leading to **478% year-over-year growth** in the Retail market vertical[13](index=13&type=chunk) - Regulatory approvals are pending in **Australia and New Zealand**, with commercial launch expected **later in 2025**, and new orders/reorders expected from countries with signed distribution agreements[13](index=13&type=chunk) [Manufacturing and Capacity](index=2&type=section&id=Manufacturing%20Expansion%20and%20Automation) The company completed its relocation to a new manufacturing facility in July 2025, equipped with new automated capabilities to meet increasing demand for Evolve products and improve capacity and gross margins - Company completed its move into a **new manufacturing facility** in **July 2025** to meet growing demand for Evolve product[13](index=13&type=chunk) - **New automated capabilities** are expected to drive **improvement in capacity and gross margins**[13](index=13&type=chunk) [Media and Brand Awareness](index=2&type=section&id=Media%20Coverage%20and%20Awareness) SenesTech continues to receive significant positive media coverage across various outlets for its unique approach to pest management, enhancing brand awareness - SenesTech continues to garner **significant positive media coverage** for its **unique approach to pest management**, with coverage across all media outlets, including Discord and X[13](index=13&type=chunk) [Financial Statements](index=4&type=section&id=Financial%20Statements) [Balance Sheets](index=4&type=section&id=BALANCE%20SHEETS) As of June 30, 2025, SenesTech's total assets significantly increased to $10.365 million from $3.278 million at December 31, 2024, primarily driven by a substantial increase in cash and cash equivalents. Total liabilities also rose, mainly due to the recognition of operating lease liabilities Balance Sheet Summary (in thousands) | Item | June 30, 2025 | December 31, 2024 | | :-------------------------- | :-------------- | :---------------- | | Cash and cash equivalents | $6,055 | $1,307 | | Total current assets | $7,474 | $2,813 | | Total assets | $10,365 | $3,278 | | Total current liabilities | $810 | $561 | | Total liabilities | $3,388 | $767 | | Total stockholders' equity | $6,977 | $2,511 | - Cash and cash equivalents increased significantly from **$1,307 thousand** at December 31, 2024, to **$6,055 thousand** at June 30, 2025[20](index=20&type=chunk) - The balance sheet reflects the introduction of a **Right to use asset, operating lease ($2,417 thousand)** and an **Operating lease liability ($2,403 thousand)** in Q2 2025[20](index=20&type=chunk) [Statements of Operations](index=5&type=section&id=STATEMENTS%20OF%20OPERATIONS) For the three months ended June 30, 2025, net revenues increased 36% year-over-year to $625,000, leading to a 64% increase in gross profit to $409,000. Despite increased operating expenses, the net loss remained stable at $(1.616) million compared to $(1.584) million in Q2 2024. Loss per share significantly improved to $(0.87) from $(3.08) due to an increase in weighted average shares outstanding Statements of Operations Summary (in thousands, except per share data) | Metric | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :---------------------------------- | :------------------------------- | :------------------------------- | :------------------------------- | :------------------------------- | | Revenues, net | $625 | $459 | $1,110 | $874 | | Cost of sales | $216 | $210 | $388 | $490 | | Gross profit | $409 | $249 | $722 | $384 | | Operating expenses | $2,023 | $1,851 | $3,999 | $3,829 | | Loss from operations | $(1,614) | $(1,602) | $(3,277) | $(3,445) | | Net loss | $(1,616) | $(1,584) | $(3,281) | $(3,416) | | Weighted average shares outstanding | 1,854,531 | 514,463 | 1,578,783 | 514,458 | | Loss per share | $(0.87) | $(3.08) | $(2.08) | $(6.64) | - Gross profit margin for Q2 2025 was **65.4%** ($409/$625), an increase from **54.2%** ($249/$459) in Q2 2024[22](index=22&type=chunk) - Loss per share improved significantly from **$(3.08)** in Q2 2024 to **$(0.87)** in Q2 2025, primarily due to a **substantial increase in weighted average shares outstanding**[22](index=22&type=chunk) [Non-GAAP Financial Measures Reconciliation](index=5&type=section&id=Itemized%20Reconciliation%20Between%20Net%20Loss%20and%20Adjusted%20EBITDA%20(non-GAAP)) SenesTech's Adjusted EBITDA loss improved to $(1.442) million in Q2 2025 from $(1.478) million in Q2 2024, reflecting a slight improvement in operational performance when excluding non-cash and one-time items Adjusted EBITDA Reconciliation (in thousands) | Metric | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :---------------------------------- | :------------------------------- | :------------------------------- | :------------------------------- | :------------------------------- | | Net loss (as reported, GAAP) | $(1,616) | $(1,584) | $(3,281) | $(3,416) | | Total non-GAAP adjustments | $174 | $106 | $333 | $215 | | Adjusted EBITDA loss (non-GAAP) | $(1,442) | $(1,478) | $(2,948) | $(3,201) | - Adjusted EBITDA loss improved by **$36 thousand** year-over-year for the three months ended June 30, 2025[24](index=24&type=chunk) [Company Information and Disclosures](index=2&type=section&id=Company%20Information%20and%20Disclosures) [About SenesTech](index=2&type=section&id=About%20SenesTech) SenesTech is a pioneer in rodent fertility control, offering EPA-registered contraceptive solutions like ContraPest® and Evolve Rat/Mouse. Their mission is to provide humane, effective, and sustainable pest management, integrating into existing IPM programs - SenesTech is the **pioneer of fertility control for rodents**, offering solutions like **ContraPest®**, the **first and only U.S. EPA-registered contraceptive** for male and female rats, and **Evolve Rat and Evolve Mouse Birth Control**[13](index=13&type=chunk)[14](index=14&type=chunk) - Their mission is to achieve **healthier cities, safer environments, and smarter pest management through reproductive control**, without compromise[14](index=14&type=chunk) [Use of Non-GAAP Measure](index=2&type=section&id=Use%20of%20Non-GAAP%20Measure) Adjusted EBITDA is presented as a non-GAAP measure to provide additional insight into operating performance and liquidity, though it is not a substitute for GAAP financial measures - **Adjusted EBITDA** is a **non-GAAP measure** included because management believes it provides meaningful information related to **operating performance and liquidity**[9](index=9&type=chunk) - This measure is **not intended to be a substitute for financial measures reported in accordance with GAAP**[9](index=9&type=chunk) [Conference Call Information](index=2&type=section&id=Conference%20Call%20Details) SenesTech hosted a conference call on Thursday, August 7, 2025, at 5:00 p.m. ET, with a webcast replay available for 90 days - Conference Call Date: **Thursday, August 7, 2025, Time: 5:00 p.m. ET**[10](index=10&type=chunk) - Webcast available at https://app.webinar.net/20BjnmenEmb, with a replay available for **90 days** on the Company's website[11](index=11&type=chunk)[12](index=12&type=chunk) [Forward-Looking Statements and Safe Harbor](index=3&type=section&id=Safe%20Harbor%20Statement) This press release contains forward-looking statements regarding future expectations, plans, and strategies, which are subject to risks and uncertainties that could cause actual results to differ materially. The company does not undertake to update these statements publicly - This press release contains **"forward-looking statements"** within the meaning of federal securities laws, subject to the **safe harbor** created thereby[16](index=16&type=chunk) - Such statements describe future expectations, plans, results, or strategies and are subject to **risks, uncertainties, and other factors** that could cause **actual results to differ materially**[16](index=16&type=chunk)[17](index=17&type=chunk) - The company does **not undertake any obligation to publicly update** any forward-looking statements, except as required by law[17](index=17&type=chunk) [Investor Relations Contact](index=3&type=section&id=CONTACT) Contact information for investor relations and the company's Chief Financial Officer is provided for inquiries - Investors can contact **Robert Blum** at **Lytham Partners, LLC**, (602) 889-9700, senestech@lythampartners.com[18](index=18&type=chunk) - Company contact: **Tom Chesterman, Chief Financial Officer, SenesTech, Inc.**, (928) 779-4143[18](index=18&type=chunk)

Core Viewpoint - SenesTech, Inc. has successfully closed the exercise of outstanding warrants, raising approximately $6.3 million, and issued new short-term warrants for additional capital [1][4]. Group 1: Financial Details - The company exercised warrants to purchase 1,458,872 shares at an exercise price of $4.15 per share [1]. - New unregistered short-term warrants were issued to purchase up to 2,188,308 shares at an exercise price of $5.25 per share, with a purchase price of $0.125 per warrant [3]. - The potential gross proceeds from the new short-term warrants, if fully exercised, could amount to approximately $11.5 million [4]. Group 2: Use of Proceeds - The net proceeds from the transaction are expected to be used for working capital and general corporate purposes [4]. Group 3: Company Overview - SenesTech is focused on humane management of animal pest populations through fertility control, with products like ContraPest® and Evolve™ [8]. - ContraPest® is the only U.S. EPA-registered contraceptive for male and female rats, while Evolve™ products are designated as minimum risk contraceptives for rodents [8].

Financial Results Announcement - SenesTech, Inc. will report its second quarter 2025 financial results for the period ended June 30, 2025, after market close on August 7, 2025 [1] - A conference call is scheduled for the same day at 5:00 p.m. Eastern time to review the results [1][2] Company Overview - SenesTech is focused on humane management of animal pest populations through fertility control, with products like ContraPest®, the only U.S. EPA-registered contraceptive for rats, and Evolve™ products for rodents [4] - The company's mission emphasizes proactive, safe, and sustainable pest management solutions, aiming for clean cities and efficient businesses [4] Webcast and Replay Information - Interested parties can access the live conference call via a webcast available on the company's Investor Relations website [2] - A replay of the webcast will be available for 90 days following the event [3]